Valvular heart disease

Affluent Medical published preclinical data in the renowned ANNALS OF THORACIC SURGERY confirming the potential of its Epygon mitral valve.

Retrieved on: 
Thursday, May 27, 2021
Medical specialties, Surgery, Anatomy, Cardiac surgery, Thoracic surgery, Mitral valve, Valvular heart disease, Heart valve, Cardiothoracic surgery, Mitral valve replacement, Charles P. Bailey, EPYGON, AFFLUENT

Affluent Medical published preclinical data in the renowned ANNALS OF THORACIC SURGERY confirming the potential of its Epygon mitral valve.

Key Points: 
  • Affluent Medical published preclinical data in the renowned ANNALS OF THORACIC SURGERY confirming the potential of its Epygon mitral valve.
  • Affluent Medical published preclinical data in the renowned ANNALS OF THORACIC SURGERY confirming the potential of its Epygon mitral valve to restore blood flow and reduce the risk of cardiac insufficiency.
  • Preclinical in vivo results published in The Annals of Thoracic Surgery confirm the Epygon mitral valve ability to adapt to the heart while restoring the native-like blood flow.
  • The company today announced the publication of preclinical data of its mitral valve Epygon in the renowned Annals of Thoracic Surgery on "Novel transcatheter mitral prosthesis designed to preserve physiological ventricular flow dynamics" ( https://www.annalsthoracicsurgery.org/article/S0003-4975(21)00646-9/fulltext ).

JenaValve Technology Receives CE Mark for its Trilogy™ TAVI System for the Treatment of Aortic Regurgitation and Aortic Stenosis

Retrieved on: 
Tuesday, May 25, 2021
Medical specialties, Circulatory system, Clinical medicine, Cardiac surgery, Valvular heart disease, Cardiology, Percutaneous aortic valve replacement, Aortic valve, Aortic stenosis, Aortic insufficiency, Regurgitation, Heart valve

The Trilogy Heart Valve System is the first transfemoral device of its kind to receive CE mark approval for the treatment of both severe symptomatic aortic regurgitation and aortic stenosis.

Key Points: 
  • The Trilogy Heart Valve System is the first transfemoral device of its kind to receive CE mark approval for the treatment of both severe symptomatic aortic regurgitation and aortic stenosis.
  • With the CE Mark, the Trilogy TAVI system becomes the first TAVI system in the world approved for the treatment of aortic regurgitation in high surgical risk patients.
  • With the Trilogy valve, we now have one aortic valve that meets the clinical demands of both aortic stenosis as well as aortic regurgitation.
  • JenaValve Technology, Inc., with locations in Irvine, California, Leeds, U.K. and Munich, Germany, develops and manufactures transcatheter aortic valve implantation (TAVI) systems to treat patients suffering from aortic valve disease.

Foldax Announces Successful First Human Use of Tria Biopolymer Mitral Heart Valve

Retrieved on: 
Tuesday, May 25, 2021
Health, Medical devices, Surgery, Research, Science, Cardiology, Biotechnology, Anatomy, Cardiac surgery, Heart, Mitral valve, Medical specialties, Heart valve, Valvular heart disease, Mitral valve repair, R. Ravi Kumar

Foldax , Inc. today announced the successful first-in-human use of its biopolymer Tria heart valve in surgically replacing a diseased mitral valve.

Key Points: 
  • Foldax , Inc. today announced the successful first-in-human use of its biopolymer Tria heart valve in surgically replacing a diseased mitral valve.
  • We are excited to be the first center in the world to implant the innovative Tria mitral valve as part of this research study.
  • In this first-in-man procedure, we saw an immediate improvement in the functionality of this patients heart valve once the valve was in place, said Dr. Heimansohn.
  • We thank Dr. Heimansohn and his skilled team at Ascension St. Vincent Hospital for their commitment to advancing cardiovascular medicine by successfully performing the first-in-man Tria mitral valve procedure, said Foldax CEO Frank Maguire.

New Survey Identifies Opportunity to Improve Shared Decision Making Between Cardiologists and Heart Valve Disease Patients

Retrieved on: 
Friday, May 14, 2021
Cardiac surgery, Medical specialties, Clinical medicine, Medicine, Aortic valve replacement, Aortic valve, Percutaneous aortic valve replacement, Aortic stenosis, Valve replacement, Valvular heart disease, Aortic valve repair, Mitral valve replacement

Currently, treatment options for AS include transcatheter aortic valve replacement (TAVR), a minimally invasive procedure, or a surgical aortic valve replacement (SAVR), also known as open heart surgery.

Key Points: 
  • Currently, treatment options for AS include transcatheter aortic valve replacement (TAVR), a minimally invasive procedure, or a surgical aortic valve replacement (SAVR), also known as open heart surgery.
  • However, more than half of cardiologists surveyed (53%) feel that their symptomatic severe AS patients are not as informed as they should be about their treatment options.\nThe findings indicate physicians recognize the importance of shared decision making to achieve individualized care for heart valve disease patients.
  • More than 3,400 responses were received from heart valve patients and caregivers.
  • Of the respondents, 94% identified as heart valve patients, 53% identified as aortic stenosis patients.\n'

Global Prosthetic Heart Valve/Artificial Heart Valve Market Trends, Forecast, and Competitive Analysis Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 20, 2021
Medical devices, Health, Medicine, Medical specialties, Cardiology, Clinical medicine, Cardiac surgery, Prosthetics, Artificial heart valve, Edwards Lifesciences, Prosthesis, Valvular heart disease, LivaNova, Artificial heart

b'The "Prosthetic Heart Valve/Artificial Heart Valve Market Report: Trends, Forecast, and Competitive Analysis" report has been added to ResearchAndMarkets.com\'s offering.\nThe global prosthetic heart valve/artificial heart valve market is expected to grow with a CAGR of 13% from 2019 to 2024.\nThe future of the prosthetic heart valve/artificial heart valve market looks promising with opportunities in the cardiovascular applications.

Key Points: 
  • b'The "Prosthetic Heart Valve/Artificial Heart Valve Market Report: Trends, Forecast, and Competitive Analysis" report has been added to ResearchAndMarkets.com\'s offering.\nThe global prosthetic heart valve/artificial heart valve market is expected to grow with a CAGR of 13% from 2019 to 2024.\nThe future of the prosthetic heart valve/artificial heart valve market looks promising with opportunities in the cardiovascular applications.
  • The major growth drivers for this market are increasing geriatric population, growing frequency of structural heart diseases, technological advancement, and rising awareness on heart valve diseases.\nThe study includes the prosthetic heart valve/artificial heart valve market size and forecast for the global prosthetic heart valve/artificial heart valve market through 2024, segmented by valve type and region.\nSome of the prosthetic heart valve/artificial heart valve companies profiled in this report include Medtronic, Edwards Lifesciences, Boston Scientific, Livanova, St. Jude Medical, Symetis, Jenavalve Technology, Cryolife, TTK Healthcare, Colibri Heart Valve, Lepu Medical Technology, and Braile Biomedica.\nSome of the features of \'Global Prosthetic Heart Valve/Artificial Heart Valve Market 2019-2024: Trends, Forecast, and Opportunity Analysis\' include:\nMarket size estimates: Global prosthetic heart valve/artificial heart valve market size estimation in terms of value ($M) shipment.\nTrend and forecast analysis: Market trend (2013-2018) and forecast (2019-2024) by segments and region.\nSegmentation analysis: Global market size by valve type and region.\nRegional analysis: Global prosthetic heart valve/artificial heart valve market breakdown by North America, Europe, Asia Pacific, and the Rest of the World.\nGrowth opportunities: Analysis on growth opportunities in different applications and regions for prosthetic heart valve/artificial heart valve in the global prosthetic heart valve/artificial heart valve market.\nStrategic analysis: This includes M&A, new product development, and competitive landscape for, prosthetic heart valve/artificial heart valve in the global prosthetic heart valve/artificial heart valve market.\nAnalysis of competitive intensity of the industry based on Porter\'s Five Forces model.\nThis report answers the following 11 key questions:\nWhat are some of the most promising potential, high-growth opportunities for the global prosthetic heart valve/artificial heart valve market?\nWhich segments will grow at a faster pace and why?\nWhich regions will grow at a faster pace and why?\nWhat are the key factors affecting market dynamics?
  • What are the drivers and challenges of the prosthetic heart valve/artificial heart valve market?\nWhat are the business risks and threats to the prosthetic heart valve/artificial heart valve market?\nWhat are emerging trends in this prosthetic heart valve/artificial heart valve market and the reasons behind them?\nWhat are some changing demands of customers in the prosthetic heart valve/artificial heart valve market?\nWhat are the new developments in the prosthetic heart valve/artificial heart valve market?
  • What strategic initiatives are being implemented by key players for business growth?\nWhat are some of the competitive products and processes in this prosthetic heart valve/artificial heart valve area and how big of a threat do they pose for loss of market share via material or product substitution?\nWhat M & A activities have taken place in the last 5 years in prosthetic heart valve/artificial heart valve market?\n3.2: Global Prosthetic Heart Valve/Artificial Heart Valve Market: Trends and Forecast\n'

Global Aortic Valve (Tissue/Biological, Mechanical) Market Report 2020-2030: Emerging Economies are Key Opportunities Area for Market Players

Retrieved on: 
Friday, April 9, 2021
Medical specialties, Cardiac surgery, Clinical medicine, Circulatory system, Valvular heart disease, Cardiology, Aortic stenosis, Aortic valve, Valve replacement, Aortic insufficiency, Regurgitation, Heart valve

The global aortic valve market is predicted to attain a revenue of $29,146.9 million by 2030, advancing at a 13.2% CAGR during the forecast period (2020-2030)

Key Points: 
  • The global aortic valve market is predicted to attain a revenue of $29,146.9 million by 2030, advancing at a 13.2% CAGR during the forecast period (2020-2030)
    A key factor leading to the growth of the market is the increasing prevalence of aortic regurgitation and aortic stenosis.
  • When procedure is taken into consideration, the aortic valve market is divided into open surgery and minimally invasive surgery (MIS), between which, the MIS division held the major value share of the market in 2019.
  • Some of the common treatments recommended for aortic stenosis are transcatheter aortic valve treatment and surgical valve replacement.
  • Companies operating in the aortic valve market are focusing widely on business mergers, strategic partnerships, product launches, and trial and approvals for remaining competitive in the domain.

Abbott Receives CE Mark Approval for Next-Generation TriClip™ Device, Offering New Innovations for Tricuspid Heart Valve Repair

Retrieved on: 
Thursday, April 8, 2021
Anatomy, Medical specialties, Heart, Cardiac surgery, Valvular heart disease, Heart valves, Cardiology, Heart valve repair, Tricuspid valve, Heart valve, Tricuspid insufficiency, Regurgitation

ABBOTT PARK, Ill., April 8, 2021 /PRNewswire/ --Abbott (NYSE: ABT) today announced it has received CE Mark for its next-generation TriClip Transcatheter Tricuspid Valve Repair System, the first-of-its-kind minimally invasive tricuspid heart valve repair device available in Europe to treat tricuspid regurgitation (TR).

Key Points: 
  • ABBOTT PARK, Ill., April 8, 2021 /PRNewswire/ --Abbott (NYSE: ABT) today announced it has received CE Mark for its next-generation TriClip Transcatheter Tricuspid Valve Repair System, the first-of-its-kind minimally invasive tricuspid heart valve repair device available in Europe to treat tricuspid regurgitation (TR).
  • The clip-based therapy, known as TriClip G4, is a non-surgical heart valve repair option specifically designed for the treatment of TR, or a leaky tricuspid valve, that allows physicians to tailor repair of the valve to each patient's unique anatomy.
  • When those leaflets do not close properly, blood can flow in the reverse direction known as regurgitation forcing the heart to work harder.
  • "This newest generation device further improves cardiologists' ability to safely and effectively repair the tricuspid valve, which historically has been extremely challenging to treat."

Cardio Industry Executive Ed Rieflin Appointed to Chair Vvital Biomed

Retrieved on: 
Wednesday, April 7, 2021
Medical specialties, Cardiac surgery, Anatomy, Heart, Valvular heart disease, Cardiology, Regurgitation, Mitral valve, Heart valve repair, Mitral insufficiency, Heart valve

MISGAV, Israel, April 7, 2021 /PRNewswire/ -- Vvital Biomed Ltd. ("Vvital"), a portfolio company of The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), announced the appointment of Ed Rieflin as Chair of the Board.

Key Points: 
  • MISGAV, Israel, April 7, 2021 /PRNewswire/ -- Vvital Biomed Ltd. ("Vvital"), a portfolio company of The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), announced the appointment of Ed Rieflin as Chair of the Board.
  • Commenting on the appointment Rieflin said, "Long-term treatment solutions to mitral valve regurgitation are the holy grail of this sector.
  • Vvital CMO, Aram Smolinsky MD, the heart surgeon who introduced mitral valve repair to Israel and inventor of the Vvital solution, further elucidates, "Vvital's procedure immediately repairs the mitral valve regurgitation.
  • Vvital CEO, Nir Golan remarked, "A true industry expert, Ed Rieflin is a great addition to our company.

Cardiac Dimensions Welcomes Robert White to its Board of Directors

Retrieved on: 
Tuesday, April 6, 2021
Anatomy, Heart, Medical specialties, Organs, Regurgitation, Mitral valve, Cardiac surgery, Valvular heart disease, Mitral valve repair

KIRKLAND, Wash., April 6, 2021 /PRNewswire/ --Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today announced the election of Robert Whiteas an independent director to its Board of Directors.

Key Points: 
  • KIRKLAND, Wash., April 6, 2021 /PRNewswire/ --Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today announced the election of Robert Whiteas an independent director to its Board of Directors.
  • "It's exciting to join a leader in the field whose innovative device is addressing the large unmet needs of patients suffering from heart failure," Mr. White commented.
  • Cardiac Dimensions is a leader in the development of innovative, minimally invasive treatments to address heart failure and related cardiovascular conditions.
  • Carnegie & Co. Cardiac Dimensions is headquartered in Kirkland, Washington and has operations in the United States, Australia and Germany.

FDA Approves First in the World Device to Treat Patients with Congenital Heart Disease

Retrieved on: 
Friday, March 26, 2021
Congenital heart defects, Cardiology, Circulatory system, Anatomy, Medical specialties, Regurgitation, Heart, Valvular heart disease, Percutaneous pulmonary valve implantation

The device is designed for patients who have severe pulmonary valve regurgitation (blood leaking backward into the right lower chamber of the heart), a condition that often results from congenital heart disease.

Key Points: 
  • The device is designed for patients who have severe pulmonary valve regurgitation (blood leaking backward into the right lower chamber of the heart), a condition that often results from congenital heart disease.
  • "The Harmony TPV provides a new treatment option for adult and pediatric patients with certain types of congenital heart disease.
  • Congenital heart defects (CHDs) are conditions that are present at birth and can affect the structure of a baby's heart and the way it works.
  • The Harmony TPV device was granted Breakthrough Device Designation for the treatment of pediatric and adult patients with severe pulmonary valve regurgitation.